📊 RMTI Key Takeaways
Is Rockwell Medical, Inc.. (RMTI) a Good Investment?
Rockwell Medical faces severe operational distress with a 31.8% YoY revenue collapse, persistent operating losses, and negative free cash flow generation. While adequate liquidity provides near-term runway, the company's profitability trajectory and cash burn are unsustainable without significant operational restructuring or market recovery.
Rockwell Medical’s fundamentals are challenged by a 31.8% YoY revenue contraction, negative operating and net margins, and weak returns (ROE/ROA). While liquidity is strong and leverage is low, interest coverage is negative and EPS deterioration suggests dilution risk; without top-line stabilization and margin expansion, a path to durable profitability remains unclear.
Why Buy Rockwell Medical, Inc.. Stock? RMTI Key Strengths
- Strong liquidity position with 3.98x current ratio and 3.63x quick ratio provides short-term solvency cushion
- Conservative capital structure with 0.24x debt-to-equity ratio limits financial leverage risk
- 11.7M in gross profit and 10.7M cash reserves provide limited operational runway
- Strong liquidity with 3.98x current and 3.63x quick ratios
- Low leverage (0.24x debt/equity) providing flexibility
- Modest cash burn with near-breakeven operating cash flow and low capex
RMTI Stock Risks: Rockwell Medical, Inc.. Investment Risks
- Catastrophic revenue decline of 31.8% YoY indicates severe market share loss, product failure, or sector headwinds
- Negative operating cash flow (-659K) and free cash flow (-1.2M) demonstrate unsustainable cash burn with negative FCF margin
- Operating losses (-4.7M) and negative net income (-5.3M) coupled with deteriorating EPS (-0.15) show worsening profitability trajectory
- Weak gross margin of 16.9% for pharmaceutical sector indicates structural operational inefficiency or unfavorable product mix
- Continued double-digit revenue declines pressure scale and fixed-cost absorption
- Persistent negative margins and returns (operating, net, ROE/ROA)
- Negative interest coverage and potential future dilution to fund operations
Key Metrics to Watch
- Revenue stabilization and return to growth trajectory
- Path to positive operating cash flow and operating margin recovery
- Gross margin expansion toward industry benchmarks (70%+)
- Cash runway depletion timeline given current burn rate
- Revenue growth (YoY and sequential)
- Gross margin and operating cash flow/FCF margin
Rockwell Medical, Inc.. (RMTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.98x current ratio provides a solid financial cushion.
RMTI Profit Margin, ROE & Profitability Analysis
RMTI vs Healthcare Sector: How Rockwell Medical, Inc.. Compares
How Rockwell Medical, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rockwell Medical, Inc.. Stock Overvalued? RMTI Valuation Analysis 2026
Based on fundamental analysis, Rockwell Medical, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rockwell Medical, Inc.. Balance Sheet: RMTI Debt, Cash & Liquidity
RMTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rockwell Medical, Inc..'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
RMTI Revenue Growth, EPS Growth & YoY Performance
RMTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.9M | $276.0K | $0.01 |
| Q2 2025 | $16.1M | $343.0K | $0.01 |
| Q1 2025 | $18.9M | -$1.5M | $-0.04 |
| Q3 2024 | $23.8M | $276.0K | $0.01 |
| Q2 2024 | $18.1M | $343.0K | $0.01 |
| Q1 2024 | $19.7M | -$1.7M | $-0.06 |
| Q3 2023 | $18.7M | -$1.8M | $-0.07 |
| Q2 2023 | $18.1M | -$1.8M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rockwell Medical, Inc.. Dividends, Buybacks & Capital Allocation
RMTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rockwell Medical, Inc.. (CIK: 0001041024)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RMTI
What is the AI rating for RMTI?
Rockwell Medical, Inc.. (RMTI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RMTI's key strengths?
Claude: Strong liquidity position with 3.98x current ratio and 3.63x quick ratio provides short-term solvency cushion. Conservative capital structure with 0.24x debt-to-equity ratio limits financial leverage risk. ChatGPT: Strong liquidity with 3.98x current and 3.63x quick ratios. Low leverage (0.24x debt/equity) providing flexibility.
What are the risks of investing in RMTI?
Claude: Catastrophic revenue decline of 31.8% YoY indicates severe market share loss, product failure, or sector headwinds. Negative operating cash flow (-659K) and free cash flow (-1.2M) demonstrate unsustainable cash burn with negative FCF margin. ChatGPT: Continued double-digit revenue declines pressure scale and fixed-cost absorption. Persistent negative margins and returns (operating, net, ROE/ROA).
What is RMTI's revenue and growth?
Rockwell Medical, Inc.. reported revenue of $69.3M.
Does RMTI pay dividends?
Rockwell Medical, Inc.. does not currently pay dividends.
Where can I find RMTI SEC filings?
Official SEC filings for Rockwell Medical, Inc.. (CIK: 0001041024) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RMTI's EPS?
Rockwell Medical, Inc.. has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RMTI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rockwell Medical, Inc.. has a SELL rating with 77% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RMTI stock overvalued or undervalued?
Valuation metrics for RMTI: ROE of -14.4% (sector avg: 15%), net margin of -7.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RMTI stock in 2026?
Our dual AI analysis gives Rockwell Medical, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RMTI's free cash flow?
Rockwell Medical, Inc..'s operating cash flow is $-659.0K, with capital expenditures of $542.0K. FCF margin is -1.7%.
How does RMTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7.7% (avg: 12%), ROE -14.4% (avg: 15%), current ratio 3.98 (avg: 2).